Spots Global Cancer Trial Database for Effect of Stellate Ganglion Block on Meniere's Disease

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Effect of Stellate Ganglion Block on Meniere's Disease

Official Title: Effect of Stellate Ganglion Block on Meniere's Disease

Study ID: NCT01574313

Conditions

Vertigo

Meniere Disease

Interventions

stellate ganglion block

0.25mg, fludiazine

25mg cephadol@ (diphenidol)

200mg kentons@ (tocopherol nicotinate).

Study Description

Brief Summary: Stellate ganglion block (SGB) has been the alternative treatment of Meniere's disease for years. However, objective evidence of the effect of SGB was still lack. The investigators conducted a randomized controlled study to examine the immediate effects of SGB in SP/AP of electrocochleography (ECoG).

Detailed Description: Ten patients were randomly assigned to receive stellate ganglion block. These ten patients made up the experimental group. Another ten patients in the control group were assigned to receiving one dosage of oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).